Melanoma Pipeline constitutes 150+ key companies continuously working towards developing 170+ Melanoma treatment therapies, analyzes DelveInsight.
Melanoma Overview:
Melanoma is a form of cancer that begins in melanocytes, the cells responsible for producing pigment. While approximately 90% of melanomas arise in the skin, the disease can also occur in the eyes, internal organs, and mucous membranes of the gastrointestinal, respiratory, and urogenital systems. It is the third most prevalent skin cancer after basal cell carcinoma and squamous cell carcinoma and ranks as the fifth most common cancer in men and sixth in women. Although widespread, melanoma has traditionally been challenging to treat, with slower drug development progress compared to other cancers.
Melanoma often spreads to the lymph nodes, lungs, liver, bones, and brain. Warning signs include abnormal skin growths, changes in existing moles—such as size increase, darkening, irregular borders, or color changes—sores that don’t heal, and skin lesions that become painful, itchy, or sensitive. Diagnosis generally begins with a visual skin assessment and the ABCDE method (asymmetry, border, color, diameter, and evolution). If melanoma is suspected, a biopsy is conducted—either a punch, excisional, or shave biopsy—to analyze the tissue. Tumor thickness is examined under a microscope, as thicker tumors have a higher chance of spreading. Further tests, including imaging (CT, MRI, PET scans) and bloodwork (such as lactate dehydrogenase levels), are used to check for metastasis.
Treatment is tailored based on the stage of melanoma and the patient's overall health. In early stages, surgery may be curative. For more advanced cases, lymph node dissection may be required to limit further spread, and metastasectomy can remove small tumor deposits in organs. Additional treatments include targeted therapies that focus on specific cancer cells, radiation, and immunotherapy—which is widely pursued by biopharmaceutical companies to boost the immune system’s ability to combat melanoma.
Request for a detailed insights report on Melanoma pipeline insights
"Melanoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Melanoma Therapeutics Market.
Key Takeaways from the Melanoma Pipeline Report
-
DelveInsight’s Melanoma pipeline report depicts a robust space with 150+ active players working to develop 170+ pipeline therapies for Melanoma treatment.
-
Key Melanoma companies such as IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, and others are evaluating new drugs for Melanoma to improve the treatment landscape.
-
Promising Melanoma pipeline therapies in various stages of development include IO102 IO103, mRNA 4157, MK-4830, BNT111, TILT 123, and others.
Recent breakthroughs in the Melanoma Pipeline Segment:
-
January 2025 – Ultimovacs ASA: A randomized, open-label study is being conducted to evaluate the efficacy and safety of UV1 vaccination in combination with nivolumab and ipilimumab as a first-line treatment for adult patients with histologically confirmed unresectable metastatic melanoma.
-
January 2025 – Regeneron Pharmaceuticals: This study is investigating the experimental drug fianlimab (REGN3767) in combination with cemiplimab (REGN2810), referred to as the "study drugs." The research focuses on melanoma patients and aims to assess the safety and effectiveness of fianlimab and cemiplimab compared to the approved combination of relatlimab and nivolumab, marketed as Opdualag™, for treating melanoma in both adults and children.
-
January 2025 – Amgen: This study aims to evaluate the efficacy, safety, and immunogenicity of ABP 206 in comparison with nivolumab in patients with treatment-naïve, unresectable, or metastatic melanoma. Participants will be randomly assigned (1:1) to receive either ABP 206 or nivolumab and will continue treatment until disease progression, unacceptable toxicity, or withdrawal of consent, for a maximum of 24 months. The total study duration for each participant is approximately 26 months.
-
In April 2024, Obsidian Therapeutics shared an update on its Phase I first-in-human trial of OBX-115 tumor-infiltrating lymphocyte (TIL) cell therapy for patients with advanced or metastatic melanoma. The update, presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, included safety data with a median follow-up of 25 weeks and newly detailed efficacy results.
-
In April 2024, Iovance Biotherapeutics announced that clinical data for lifileucel combined with pembrolizumab in frontline advanced melanoma, along with translational data, would be featured at the 2024 ASCO Annual Meeting.
Melanoma Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Melanoma Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Melanoma treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Melanoma market.
Download our free sample page report on Melanoma pipeline insights
Melanoma Emerging Drugs
-
IO102 IO103 : IO Biotech
-
mRNA 4157: Moderna Inc.
-
MK-4830: Merck Sharp & Dohme LLC
-
BNT111: BioNTech SE
-
TILT 123: TILT Biotherapeutics LLC
Melanoma Companies
Around 150 key companies are actively developing therapies for colorectal cancer. Among them, IO Biotech has a melanoma drug candidate in the most advanced stage of development, specifically Phase III clinical trials.
DelveInsight’s report covers around 170+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Melanoma Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Melanoma Therapies and Key Companies: Melanoma Clinical Trials and advancements
Melanoma Pipeline Therapeutic Assessment
• Melanoma Assessment by Product Type
• Melanoma By Stage
• Melanoma Assessment by Route of Administration
• Melanoma Assessment by Molecule Type
Download Melanoma Sample report to know in detail about the Melanoma treatment market @ Melanoma Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Melanoma Current Treatment Patterns
4. Melanoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Melanoma Late-Stage Products (Phase-III)
7. Melanoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Melanoma Discontinued Products
13. Melanoma Product Profiles
14. Melanoma Key Companies
15. Melanoma Key Products
16. Dormant and Discontinued Products
17. Melanoma Unmet Needs
18. Melanoma Future Perspectives
19. Melanoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Melanoma Pipeline Reports Offerings
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
